Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 16/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149035 | 0.91 | KRAS (0.36) | KRASMAPK3MAPK1RAF1 | |
| SCHEMBL30148987 | 0.91 | KRAS (0.36) | KRASMAPK3MAPK1RAF1JAK1 | |
| SCHEMBL31669685 | 0.90 | GPR119 (0.36) | KRASGPR119MAPK3MAPK1JAK1 | |
| SCHEMBL30841170 | 0.90 | GPR119 (0.36) | KRASGPR119MAPK3MAPK1JAK1 | |
| SCHEMBL25437918 | 0.89 | GPR119 (0.36) | KRASGPR119MAPK3MAPK1RAF1 | |
| SCHEMBL30149022 | 0.89 | GPR119 (0.36) | KRASGPR119MAPK3MAPK1RAF1 | |
| SCHEMBL30149131 | 0.89 | GPR119 (0.36) | KRASGPR119MAPK3MAPK1RAF1 | |
| SCHEMBL30959903 | 0.86 | KRAS (0.40) | KRASGPR119JAK1 | |
| SCHEMBL31441816 | 0.86 | KRAS (0.40) | KRASGPR119JAK1 | |
| SCHEMBL25263610 | 0.86 | KRAS (0.40) | KRASGPR119JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293558-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-2022266206-A1 | KRAS INHIBITOR CONJUGATES | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293558-A1 | KRAS INHIBITOR CONJUGATES | KRAS, MDM2, NRAS | KRAS 1/4885GPR119 3086/4885MAPK3 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.